IBEX 35
10.893,70 +39,30 (+0,36%) Euro Stoxx 50
4.893,27 -27,95 (-0,57%) Dólar/Euro
1,0727 +0,0009 (+0,09%) Petróleo Brent
84,06 +0,62 (+0,74%) Oro
2.320,00 +9,00 (+0,39%) Bitcoin EUR
53.770,52 +22,32 (+0,04%)
Evotec SE (EVT.DE)
Evotec SE
Essener Bogen 7
Hamburg 22419
Germany
49 40 560 81 0
https://www.evotec.com
Sector(es): Healthcare
Sector: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 5061
Descripción
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Gobierno corporativo
El ISS Governance QualityScore de Evotec SE, a día 29 de abril de 2024, es 5. Las puntuaciones base son Auditoría: 3; Tablero: 2; Derechos de los accionistas: 1; Compensación: 7.
